



## **BioLight's New Investment in Tarsius Pharma Ltd. that develops a novel platform for the treatment of blinding ocular diseases**

Tel Aviv (October 6, 2019) – BioLight is pleased to announce that on October 3, 2019, it has signed a binding Simple Agreement for Future Equity (SAFE), together with other investors, for investment in Tarsius Pharma Ltd. (the “**Agreement**” and “**Tarsius**”), a private Israeli company developing a novel platform for the treatment of blinding ocular diseases.

According to the Agreement, BioLight shall invest at the date of signature of the Agreement, approx. USD 1M out of a total investment of up to USD 1.5M (the “**Total Investment**”). Assuming Total Investment, the Company shall hold, following the lapse of 18 months from the date of signature (or earlier, in the occurrence of events as detailed in the Agreement) (the “**Effective Date**”), such number of shares of the most senior series of shares (Senior Shares) issued in Tarsius at the Effective Date, that shall grant BioLight, at the date hereof, approx. 4.5% of issued and fully paid up share capital of Tarsius on a fully diluted basis.

To BioLight's best knowledge, the Total Investment proceeds shall be used in accordance with Tarsius' on going activities, including the advancement of its research and development activities and enrollment in Tarsius' planned Phase I/II clinical trial in the U.S. of the TRS01, Tarsius' novel drug for the treatment of blinding ocular diseases (“**Tarsius' TRS01**”).

To BioLight's best knowledge, Tarsius recently announced the acceptance of its Investigational New Drug (IND) application for the Tarsius' TRS01 by the U.S. Food and Drug Administration (FDA).

The investment in Tarsius, joining BioLight's recent investment in Sanoculis Ltd., is aligned with BioLight's business strategy objectives and plans, and is in-line with its Ophthalmic core activity.